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Abstract
Background: Recently, mass spectrometry data have been mined using a genetic algorithm to
produce discriminatory models that distinguish healthy individuals from those with cancer. This
algorithm is the basis for claims of 100% sensitivity and specificity in two related publicly available
datasets. To date, no detailed attempts have been made to explore the properties of this genetic
algorithm within proteomic applications. Here the algorithm's performance on these datasets is
evaluated relative to other methods.
Results: In reproducing the method, some modifications of the algorithm as it is described are
necessary to get good performance. After modification, a cross-validation approach to model
selection is used. The overall classification accuracy is comparable though not superior to other
approaches considered. Also, some aspects of the process rely upon random sampling and thus for
a fixed dataset the algorithm can produce many different models. This raises questions about how
to choose among competing models. How this choice is made is important for interpreting
sensitivity and specificity results as merely choosing the model with lowest test set error rate leads
to overestimates of model performance.
Conclusions: The algorithm needs to be modified to reduce variability and care must be taken in
how to choose among competing models. Results derived from this algorithm must be
accompanied by a full description of model selection procedures to give confidence that the
reported accuracy is not overstated.
Background
When Petricoin et al. [1] published their analysis using
serum to distinguish individuals with ovarian cancer from
individuals with benign conditions, it suggested great
promise in using high throughput mass spectrometry to
improve upon existing biomarkers for patient groups that
could greatly benefit from accurate and early diagnosis.
Results from the analyses using this algorithm have, along
with early findings from other groups (e.g. [2,3]), fueled
an explosion of interest in using mass spectrometry tech-
niques for quick and accurate diagnosis. Many other
investigators have since used classification techniques to
achieve impressive results in correctly categorizing unla-
beled mass spectrometry samples as either diseased or
healthy. Among the more common classification meth-
ods used are classification trees [2], boosting [4], stepwise
discrimination methods [5], and wavelet discrimination
[6], though few have used a genetic algorithm. Baggerly et
al. [7] do use a genetic algorithm though its properties are
substantially different than that used in the earlier studies
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below. Here we evaluate the performance of a genetic
algorithm described in the original Lancet paper and sub-
sequent studies [8,9].
Description of the algorithm
The specifics of the genetic algorithm used here are based
on webpages at the NCI-FDA website housing the data
[10] and [1,9]. As the descriptions are limited, this
attempt to reproduce the algorithm may differ from the
implementation supporting the published results.
• As described, the genetic algorithm (GA) seeks to find a
collection of markers that separate cases and controls.
Here the markers correspond to a biological sample's
measurements at a given set of m/z values. In the GA
framework such a collection of markers is called a chro-
mosome. Each chromosome is evaluated by a fitness func-
tion in the following way. Suppose a given chromosome
is composed of N "genes" (i.e. N m/z values in this case).
Each sample's intensity values at the N genes are linearly
scaled to lie between 0 and 1; the smallest of the N inten-
sities is assigned 0, the largest assigned 1, and intermedi-
ate values interpolated in a linear way. The first sample is
assigned its own cluster with centroid (i.e. mean values)
given by its N values. The next sample is compared to the
first and if the Euclidean distance between the two sam-
ples exceeds .1·  then the second sample is assigned a
new cluster with centroid given by its values. If the dis-
tance is less than this limit the second sample is assigned
to the first cluster and the centroid values recalculated as
the mean of both cases. Subsequent cases are handled
similarly – if a sample's representation as an N dimen-
sional point lies within the .1·  limit of a cluster the
case is assigned to the closest cluster and centroid values
are recalculated. If the smallest distance to any cluster cen-
troid exceeds the limit then the case is assigned a new clus-
ter. When all the cases are clustered a cluster's type is
designated by majority vote – those clusters composed
mostly of cancer cases are deemed cancer clusters and
those composed mostly of nondiseased are likewise
defined. The fitness function then computes the chromo-
some's fitness as its classification accuracy, i.e. the propor-
tion of cases assigned to a cluster of the appropriate type.
• The selection process starts with 1500 randomly chosen
chromosomes, i.e. sets of markers. The documentation
indicates that chromosomes with length between 5 and
20 markers are used. In this implementation, different
chromosomes may have different lengths – the 1500 are
chosen to have a length between 5 and 20 with a uniform
probability of 1/16 governing the choice. It is not clear
how the original GA treated chromosomes of different
length.
Each of the 1500 chromosomes is evaluated by the fitness
function as described above. Chromosome pairs are then
produced with the likelihood of being selected for a pair
related to the fitness function. The available documenta-
tion does not make clear how this probability is explicitly
related to the fitness. Here the choice was made by rank-
ing the fitness scores and setting parameters α and β such
that
Prob [ selecting kth ranked chromosome ] = α + βk
where α and β were chosen such that
This approach is described in section 2.1 of [11] – ranking
is preferred to absolute fitness values as it avoids some
potential problems with scaling. An alternative method
based on absolute fitness values produced qualitatively
similar findings (results not shown).
• A new generation of chromosomes is produced by first
creating 750 parent pairs from the set of 1500 chromo-
somes. A parent pair is created by choosing two of the
1500 chromosomes using the above probabilities. A given
chromosome can be chosen to be in more than one pair.
For a given pair each chromosome is broken to produce
two sub-chromosomes. The location of the break is ran-
dom with uniform probabilities. The two sets of sub-chro-
mosomes are then crossed-over to produce two new
chromosomes. As an example suppose chromosome 1 has
genes = (3001, 5500, 7800, 11011, 13059) and chromo-
some 2 is composed of m/z locations = (2500, 4200, 909,
15002) and the first chromosome breaks between its sec-
ond and third elements while the second chromosome
breaks after its third. Then the resulting new chromo-
somes are (3001, 5500, 15002) and (2500, 4200, 909,
7800, 11011, 13059). In this way the 750 pairs of chosen
chromosomes produce a next generation of 1500 chro-
mosomes. At this point each gene in each new chromo-
some may be randomly changed to any other gene in the
entire spectrum range with probability .0002 (this corre-
sponds to genetic mutation). In our implementation it is
possible to match sub-chromosomes that would merge to
be longer than 20 units. In this event the chromosome is
truncated to 20. Further, here it is allowed to have chro-
mosomes composed of as few as 2 markers as there
seemed no compelling reason to impose a lower limit of
5 m/z values as described in the documentation. It is
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overs to pairs with the same length.
• After mutation this new generation of 1500 chromo-
somes is then evaluated by the fitness test and then
another round of selection, cross-over, and mutation
processes produce the next generation. Typically, the aver-
age fitness of generations increases over time. According
to the documentation, the process stops 1) after 250 gen-
erations, or 2) when a perfectly discriminating chromo-
some is found. In the first instance, that model that has
produced the highest fitness score is chosen.
• Given a chosen model derived from a training set, an
unlabeled spectrum (e.g. test set spectrum) is classified by
determining that cluster with the centroid that lies closest
to the unlabeled case and assigning the label of the cluster.
The documentation describes a second, related approach
that is to make this assignment only if the nearest centroid
is with .1· ; otherwise assign the case as of a third,
unknown/new type. In this current work, classification
errors for a test set correspond to the first criteria of nearest
centroid, without the .1·  requirement. Empirically,
this led to greater classification accuracy.
Some concerns about this algorithm have been raised by
others [7]; a few issues will be examined below in more
detail.
• Each chromosome is evaluated by a fitness function that
measures how well the chromosome classifies the training
set. However it is clear that the order in which the cases are
considered may make a difference in what cluster a case is
assigned as well as the clusters' centroid values. Conse-
quently, different results may arise in attempts to replicate
findings.
• The GA algorithm starts with a random selection of 1500
chromosomes and then letting these evolve through a ran-
dom mating process. As the initial selection and evolu-
tionary process is random it is again the case that different
ultimate models may be chosen, depending on the seed of
a random number generator.
• In this application, each chromosome partitions the
samples of the training set into clusters defined as groups
of cases with centroids that are at least
.1·  apart from one another. It is
not uncommon to find chromosomes that partition per-
fectly, but rely upon a large number of clusters (e.g. > 30).
This suggests overfitting of data. As described, this algo-
rithm does not penalize or otherwise take into account the
number of clusters or length of chromosomes.
Largely because of insufficient information, this imple-
mentation of the algorithm likely differs from that sup-
porting the published results. However, some elements
should be the same. In particular, the evaluation of the fit-
ness function should yield the same results except for the
issue of how the order of the cases can change the clusters'
attributes. Therefore, we should be able to match or come
close to verifying the published results for a given model.
However, our results are likely to be different as far as gen-
erating best models. This is in part due to the inherent ran-
domness the process employs as well as possible
differences in how the fitness function scores generate
members of the next generation.
Datasets
Two publicly available datasets were used to evaluate the
algorithm; information regarding them is available from
an NCI-FDA website [10]. Both datasets consist of ovarian
cancer patients and healthy controls. The first dataset,
hereafter referred to as DS1, contains "low resolution"
mass spectrometry data from a Ciphergen instrument and
is identified on the NCI-FDA website as the 8-7-02 data.
The data consist of 162 ovarian cancer samples and 91
control samples. The second dataset, DS2, contains "high
resolution" data from a hybrid quadrupole time-of-flight
spectrometer. Description and analysis of these data are
available in [12]. The dataset contains spectra from 121
cancer samples and 95 controls.
For both datasets GA-produced models are presented on
the NCI-FDA website that were developed from a training
set and perfectly discriminate a test set. There is no desig-
nation as to which individuals were used for training and
which for testing.
Results
The NCI-FDA website shows the chromosome consisting
of m/z values {435.46, 465.57, 2760.67, 3497.55,
6631.70, 14051.98, 19643.41} was able to perfectly dis-
criminate a test set drawn from the low resolution dataset,
DSl. The 253 samples were randomly split into a training
set of 81 cancer and 46 control individuals with the
remainder forming a test set. Here we illustrate how the
test set looks for these seven markers. Figure 1 shows the
ratio of the second marker (molecular weight of 465.6) to
the first (weight of 435.5) does an excellent job in separat-
ing the two types of samples in the test dataset. In the
training set only two clusters were determined – one com-
posed completely of cancer cases and the other solely of
controls. In the test dataset one sample is misclassified
(essentially because of its values on the remaining 5 mark-
ers) though it should be again pointed out that the
number of misclassifications does vary by the order in
which samples are processed and how the cases are split
into test and training sets. Ten consecutive trials in which
N
N
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randomly made produced 1, 0, 0, 0, 0, 0, 0, 0, 5, and 1
errors (all misclassifications of normal as cancer) for this
7 marker model.
This exercise verifies that the model does quite well
though it establishes that results do change with ordering
and test/training set splits. Also, it confirms that results of
100% accuracy should be understood to depend upon the
Test set classification of DS1 via 7 markersFigur  1
Test set classification of DS1 via 7 markers
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tance when the goal is to develop tests with sensitivity and
specificity exceeding 99% [12].
Next, the GA developed for this paper was then applied to
these data with the expectation it should produce some-
thing like the 7 marker chromosome given above. After 7
generations, a chromosome was found that perfectly split
the training set, but 7 clusters were required and 10 mark-
ers were used.
The graph of test set classification, Figure 2, shows a less
compelling picture of discrimination; the third marker is
perhaps best (based on t-test p-values) at distinguishing
samples. This marker corresponds to a molecular weight
of 831.1 Daltons. To examine robustness the algorithm
was run 9 more instances using different initial sets of
1500 chromosomes to try to get a sense of the variation in
the algorithm's chosen models. The same ordering, test
samples, and training samples were maintained.
In each case a perfectly discriminating (i.e. training set
error of 0%) chromosome was found within a few gener-
ations. Table 1 shows that there is considerable variation
in the test set accuracies given they were all produced by
the same data. Further, the best discriminating single
marker within the chosen chromosome shows little con-
sistency. Also, the set of 10 generally shows a large
number of clusters and markers – nothing very similar to
the published model that contained only two clusters.
The results in Table 1 suggest there are many markers that
are different in these data and it is easy to find classifiers
that performs well – at least in the training set. However,
it is also clear this creates a kind of algorithmic instability
in that considerable variation in results can arise from the
same training set data. Even if one uses a fixed training/
test set division there is now a question of how does one
decide which results to use? One could run the algorithm
just once, but run the risk of choosing a not very good
model (e.g. the model with 24 clusters and 16 markers).
However, if the algorithm is run many times in the search
for a good model, the reported sensitivity and specificity
in the test set are likely to be biased. This question will be
pursued further in the Discussion section below.
Table 1 and the preceding discussion of variation suggest
this implementation of the algorithm might be improved
by changing the procedure to favor models with fewer
clusters/markers. In this way, those models that may over-
fit the training data are penalized and the number of per-
fect discriminators of the training set consequently
reduced. A simple way of doing this is to alter the fitness
function to penalize large numbers of clusters and/or
markers. In the analysis above the fitness function was
given as
Fitness = Accuracy
= % Correctly classified cases.
This could now be modified to
Fitness = % Correctly classified cases
- p1·# of clusters
- p2·# of markers
where p1 and p2 are non-negative penalization weights.
A resampling method was used to determine the perform-
ance of different parameter combinations of p1 among {0,
.002, .005, .008} and p2 in {0, .001, .002}. Specifically,
random training samples (chosen without replacement)
were selected from the entire set of samples so the original
training sample size of 127 was maintained with 81 can-
cer and 46 control spectra. Then, for a given pair of p1 and
p2 values the GA was trained on this pseudo-random train-
ing set and a model chosen. The remaining cases that were
omitted from the training set (81 cancer and 45 control)
were then treated as a test set. We repeat this procedure for
50 randomly chosen training sets and examine the distri-
bution of the test set classification accuracy for the differ-
ent parameter combinations. The same 50 training and
test sets were used for each set of p1 and p2 combinations.
In addition to illustrating the test set accuracy, the number
of clusters, the number of markers associated with the dif-
ferent GA models, and the proportion of times (out of 50)
a perfectly discriminating chromosome was found (for
the training set) are also indicated.
This procedure gives a sense for the performance of the
algorithm for different parameter combinations. Another
Table 1: Variation in results of GA applied 10 times
Generations Test Set Errors Clusters Markers Primary m/z
7 6(5%) 7 10 831.1
14 10(8%) 24 16 617.7
9 2(2%) 8 19 246.7
6 4(3%) 21 7 632.6
13 8(6%) 13 14 226.9
5 9(7%) 7 20 42.6
9 4(3%) 5 11 831.1
9 7(6%) 30 10 617.7
9 1(1%) 7 11 786.5
7 1(1%) 5 17 42.6Page 5 of 13
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incorporated into the procedure. This was assessed in the
following way. For each of the 50 training sets, an addi-
tional 5-fold cross-validation determined which of the 12
p1 and p2 combinations performed best in terms of pre-
dicting the omitted cases (in the event of ties the model
associated with the most restrictive p1 and p2 was chosen
with p1 the first tie-breaker). The chosen parameters were
then used with the entire training set to develop a model
that was evaluated on the associated test set. As before,
this procedure was performed on the same 50 training
and test sets. In the tables that follow, the results for this
Test set classification of DS1 via 10 markersFigur  2
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most representative of overall performance for the algo-
rithm developed here.
As a means of comparison two other classification
schemes were applied to the same bootstrap samples.
Boosting is a general method of combining a weighted set
of classifiers that each "vote" on the class of a sample in
question with majority vote dictating the set's aggregate
classification. It has been successfully used in classifica-
tion of mass spectrometry data [4,13]. Here, the base clas-
sifier is a simple threshold classifier, e.g. if intensity at
mass 245.8 ≤ 47.5 then classify as cancer, otherwise clas-
sify as normal. The general process by which the set of
base classifiers is chosen is discussed at length in [4] and
[14]. Here 150 was chosen as the number of base
classifiers for the aggregate classifier and the algorithm
generally followed that outlined in section 10.1 of [14].
The second algorithm used was PAM (Predictive Analysis
for Microarrays), a shrunken centroid method of classifi-
cation [15]. This method has been used for high dimen-
sional microarray studies and is relatively easy to
implement. Both methods require little operator assisted
tuning to obtain a small feature set – an important consid-
eration when conducting so many resamplings. For these
methods the data were normalized (test and training sets
normalized separately for each resampling) so each spec-
Table 2: Accuracy percentiles and characteristics of models from 50 cross-validation samples of DS1, m/z > 0
Algorithm Test Set Accuracy 25th, 75th 
Percentile
Median # Clusters Median # Markers Proportion of Perfect 
Chromosomes
GA(P1 = 0, p2 = 0) .96, .98 12 15.5 1.0
GA(0, .001) .95, .99 12.5 11 1.0
GA(0, .002) .95, .98 12.5 10 1.0
GA(.002, 0) .96, .98 7 16 .98
GA(.002, .001) .97, .98 7 12.5 1.0
GA(.002, .002) .96, .99 8.5 9 .98
GA(.005, 0) .96, .98 6 15 .92
GA(.005, .001) .96, .98 5 11 .92
GA(.005, .002) .96, .99 6 8 .94
GA(.008, 0) .96, .98 3 15 .72
GA(.008, .001) .97, .99 4 9 .88
GA(.008, .002) .97, .99 4 8 .84
Best GA .97, .99 6 12 .94
Boosting .99, 1.0 NA NA NA
PAM .93, .97 NA NA NA
Table 3: Accuracy percentiles and characteristics of models from 50 cross-validation samples of DS1, m/z > 1500
Algorithm Test Set Accuracy 25th, 75th 
Percentile
Median # Clusters Median # Markers Proportion of Perfect 
Chromosomes
GA(p1 = 0, p2 = 0) .83, .87 90 11 1.0
GA(0, .001) .80, .87 93 11 1.0
GA(0, .002) .82, .87 92.5 9 1.0
GA(.002, 0) .87, .92 12 19 .26
GA(.002, .001) .90, .93 14 13 .38
GA(.002, .002) .88, .92 13 7.5 .20
GA(.005, 0) .87, .92 5 20 .02
GA(.005, .001) .87, .90 5 10 .02
GA(.005, .002) .87, .92 5 6.5 0
GA(.008, 0) .85, .90 3.5 18.5 0
GA(.008, .001) .85, .89 4 8.5 0
GA(.008, .002) .85, .90 4 6 0
Best GA .87, .91 7 10 .12
Boosting .93, .97 NA NA NA
PAM .80, .84 NA NA NAPage 7 of 13
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restricted to those m/z values showing Bonferroni-cor-
rected differential expression (calculated anew for each
resampling). Computer code and information regarding
the parameters and details of these methods are available
on a webpage [16] with supporting documentation.
Table 2 shows the 25th and 75th percentiles for test set
accuracy among 50 samples as described above. The two
penalty parameters have the desired effect in reducing the
number of clusters/markers but there is relatively small
variation over the different parameter combinations. The
GA models apparently perform a bit better than PAM and
a little worse than the boosting method though all models
have high accuracy. Some reviewers of these data [5,17],
have questioned why the groups are so easy to classify and
whether the entire m/z range should be used. The criticism
centers around the strong signals that are present in very
low m/z values (e.g. 2.79 and 245.54 Daltons) that are
speculated to be products of experimental procedures
rather than reflective of biological differences. Other
investigators [2] routinely exclude the lower end of the
spectrum (less than 1500 or 2000 Daltons) as they feel it
too contaminated by matrix and other effects to be clearly
interpretable. As a result of these concerns the experiment
was rerun with the m/z range restricted to be greater than
1500 Daltons.
Table 3 is based upon the m/z restricted dataset and shows
evidence of greater spread among the different GA models
– those with p1 = 0 or .008 do not appear to do as well as
p1 = .002 or .005. With no penalty on the number of clus-
ters one sees very high dimensional models (median
number of clusters > 90), perfect training set performance
every time, and relatively poor test set performance indi-
cating some type of penalization is necessary. Increasing
the value of p2 has the desired effect of yielding more par-
simonious models without an obvious decline in per-
formance. As before, the GA models seem to perform
better than PAM but less well relative to the boosting
model.
Next, results from the high resolution dataset are pre-
sented. The data require preprocessing. Some samples
contain raw data from approximately 370,000 m/z values
in the 700 – 12,000 Dalton range while other samples
have about 330,000 data points. This discrepancy is par-
ticularly worrisome as the cancer samples appear more
likely to have fewer datapoints. The information pre-
sented at the NCI-FDA website and in [12] includes some
discussion of how the data were aggregated. The imple-
mentation in this work is similar to that described at the
NCI-FDA website – details are available at a webpage con-
taining supporting material [16]. After aggregation, the
resulting spectra containing 7106 points were normalized
to have the same average intensity. We note (data not pre-
sented) that while the models for the high resolution
dataset on the NCI-FDA website have relatively good test
set performance (accuracy of about 95%) they entail a
large number of clusters – typically between 30 and 50.
This is in contrast to the model reported for the low reso-
lution DS1 Ciphergen data that had two clusters.
The results in Table 4 are quite similar to those reported
for DS1 in the m/z >1500 range in that poorly performing
high dimensional models are associated with p1 = 0 and
the GA appears to again perform at an intermediate level.
Table 4: Accuracy percentiles and characteristics of models from 50 cross-validation samples of DS2, 700 <m/z < 12000
Algorithm Test Set Accuracy 25th, 75th Median # Clusters Median # Markers Proportion of Perfect 
Chromosomes
GA(p1 = 0, p2 = 0) .70, .80 91.5 17 1.0
GA(0, .001) .63, .75 100 11 1.0
GA(0, .002) .61, .74 100 10 1.0
GA(.002, 0) .89, .93 22.5 19.5 .86
GA(.002, .001) .88, .93 22 14.5 .90
GA(.002, .002) .87, .91 22 8 .86
GA(.005, 0) .88, .93 7 19 .20
GA(.005, .001) .88, .93 7 11 .20
GA(.005, .002) .87, .93 7 6 .16
GA(.008, 0) .86, .91 5 18 .02
GA(.008, .001) .86, .91 5 10 .04
GA(.008, .002) .86, .91 5 4 .02
Best GA .88, .93 7 12 .24
Boosting .92, .95 NA NA NA
PAM .83, .86 NA NA NAPage 8 of 13
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As implemented here, the genetic algorithm without pen-
alties produces a large number of chromosomes that can
perfectly discriminate a training set of the type considered
here. For the last two analyses (DS1 with m/z > 1500 and
DS2) those models produced with p1 = 0 are associated
with a large number of clusters (median ≥ 90), indicating
that many clusters have only 1 or 2 individuals. As dem-
onstrated above, a resampling approach shows that mod-
els with large numbers of clusters will generally not
perform as well as more parsimonious chromosomes and
the use of penalization parameters greatly improves
performance.
While this modification results in better models it does
not address the other fundamental question of how to
choose a final model. Because of their reliance on random
choices GA models can and, for these data, will present
very different solutions from a given dataset. Therefore,
even if one uses a supplemental cross-validation process
to choose some ideal set of penalization parameters many
different models can be chosen by running the GA repeat-
edly. This is in contrast to many other means (e.g.
boosting, discrimination methods) that have no such reli-
ance on random processes and will produce the same
answer given a fixed dataset and parameters. Some meth-
ods such as decision trees and PAM employ cross-valida-
tion as part of their fitting process and therefore do have a
random component, but the results are not nearly so var-
iable, at least for the data considered here. Next we
explore some consequences when the GA is repeatedly
applied to a fixed training and test set with the goal of
finding "best" or superior models. Such repeated exami-
nation of test set performance violates the principal of
evaluating the test set only after the model has been
selected [14].
Consequences of repeated model fitting
Given a model developed on a training set, the perform-
ance of such a model on an independent test set is an
unbiased estimate of its performance when exposed to a
subsequent group of unlabeled cases that are generated by
the same process. However, the situation becomes more
complicated when a collection of models is considered. It
is generally not true that the best performing model
(judged by which model attains highest test set accuracy)
will reproduce similar results on a yet another group of
cases. Essentially, while every model has a true error rate,
its performance on a particular test set is a function of
both the true error and random variation. The best per-
forming model is likely the beneficiary of positive random
variation that is unlikely to be repeated in application to
yet another set of data. In this sense the best performing
model has an underestimated error rate when the selec-
tion of the best model is performed via repeated examina-
tion of a test set. We present a final set of bootstrap based
analyses to illustrate the degree of bias.
For DS1, 50 runs of the following type of experiment were
performed. First, a bootstrap sample of size 253 with 162
cancer and 91 controls is drawn (the cancer and control
individuals were bootstrapped separately from their
respective cohorts). This is denoted as Xb while the origi-
nal cohort is X. This bootstrap sample is then split into
training (81 cancer, 46 control) and test sets (81 cancer,
45 control). On the training part of the bootstrap sample
the GA is run with p1 = .005 and p2 = .001. These parame-
ters were chosen as they seemed to perform relatively well
in Tables 2, 3, and 4 and they generally employed a
smaller number of clusters and markers. The GA produced
a model associated with this particular bootstrap sample,
denoted . The performance of that model was
then evaluated by the error rate in the test set portion of
the bootstrap sample, denoted . Because the
GA process produces different estimates when run on the
same data due to randomness as described above, the
model-fitting process is then repeated 19 more times on
the same bootstrap sample to obtain 20 different models
 and 20 different measures of
performance . The order of the
training set and random sampling decisions made by the
GA were allowed to vary though the composition of the
test and training set were fixed for a given bootstrap sam-
ple. The best model, denoted , was chosen as that
among the 20 with lowest classification error, .
In the event of a tie, the number of clusters served as a tie-
breaker (smaller is better). This procedure is meant to
mimic the idea of applying 20 models to the test set and
settling upon the best one. To get an idea of the bias in
estimation error we then examine how the chosen, best
model performs for the original cohort of 253 cases – this
error rate is denoted as  and the bias estimated
by . This procedure was performed
50 times and one obtains an estimate of the distribution
of the bias from
in 1) DS1 using the whole m/z range, 2) DS1 restricting
the range to m/z > 1500, and 3) DS2 with 700 <m/z <
12000 (using different corresponding sample sizes). The
use of the bootstrap to assess bias in this way conforms to
the notion of treating the full sample distribution like a
population distribution and the bootstrap sample distri-
m Xb b1( )
e m Xb b( ( ))1
{ ( ) : ... }m X ii
b b = 1 20
{ ( ( )) : ... }e m X ii
b b = 1 20
m Xb b*( )
e m Xb b( ( ))*
e m Xb( ( ))*
e m X e m Xb b b( ( )) ( ( ))* *−
{ ( ( )) ( ( )) : ... }* *e m X e m X b
b b b− = 1 50Page 9 of 13
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[18].
The results in Table 5 show the degree of bias is relatively
modest in the first dataset – on the order of 2% and some-
what higher (median of 4–5%) in the other data under
consideration. This may not be of great practical import
unless one is particularly concerned that the specificity be
near 100% to justify using such tests on the basis of wide-
spread diagnostic testing [12]. The degree of bias is
influenced by, among other things, the number of times
the test set is interrogated – here the figure used was 20
and it may be that greater bias is associated with increased
searching. This analysis could also have been performed
by splitting the data into 3 datasets (training, test, and bias
assessment groups) though these datasets are small
enough that the bootstrap approach was preferred in that
it makes more efficient use of the data.
Generalizing results
There is considerable controversy regarding these ovarian
cancer datasets – particularly with respect to whether the
multitude of models with high or perfect sensitivity and
specificity are more the result of rich complexity reflecting
true biological variation [19,20] or flaws in experimental
design [5,17]. While it is of paramount importance to
know if true biological difference or flaws in experimental
design are primarily responsible for the ease with which
classification algorithms can separate the cancer and nor-
mal spectra (especially the low resolution dataset with 0
<m/z <20000 Daltons), the algorithms' performances will
not change regardless of the answer to this question.
Therefore, in the limited context of algorithmic perform-
ance considered here this critical issue is of secondary
importance and not addressed. This observation indicates
that these algorithmic analyses may still be valuable even
if one believes the datasets to be flawed.
Table 5: Percentiles relating to bias of repeated examinations of a test set
Percentile
10th 25th 50th 75th 90th
DS1, m/z > 0
Bootstrap smallest error: 0.0 0.0 0.0 0.0 0.0
Original cohort error: .01 .01 .02 .03 .05
Estimated bias: .003 .012 .020, .032 .051
DS1, m/z > 1500
Bootstrap smallest error: .02 .02 .03 .05 .06
Original cohort error: .07 .07 .08 .11 .13
Estimated bias: .02 .04 .05, .07 .10
DS2, 700 <m/z < 12000
Bootstrap smallest error: .01 .02 .03 .04 .05
Original cohort error: .04 .05 .06 .08 .10
Estimated bias: .01 .03 .04, .06 .07
e m Xb b( ( ))*
e m Xb( ( ))*
e m X e m Xb b b( ( )) ( ( ))* *−
e m Xb b( ( ))*
e m Xb( ( ))*
e m X e m Xb b b( ( )) ( ( ))* *−
e m Xb b( ( ))*
e m Xb( ( ))*
e m X e m Xb b b( ( )) ( ( ))* *−Page 10 of 13
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three different datasets and speculate on its performance
in other circumstances. The results in Table 5 regarding
bias arising from multiple applications of the GA do vary
somewhat among the three datasets under consideration.
Because the spectra in the full, low resolution dataset (0
<m/z < 20000 Daltons) are easiest to correctly classify (as
seen in Table 2) this dataset shows the smallest degree of
bias arising from multiple applications of the GA – the
median bias is about 2% in Table 5. Essentially the bias is
low because the normal and cancer samples are so distinct
and many models do very well. This is the case even
though the multiple models may look very different from
one another and use different primary m/z values to dis-
criminate; in this case the bias is low because virtually all
the dissimilar models do quite well.
The truncated, low resolution dataset (m/z > 1500 Dal-
tons) was used to exclude the lower mass values that some
[21] believe are difficult to interpret. Exclusion of these
masses made the spectra harder to classify (see Table 3)
and the associated bias in Table 5 was greater. The GA's
performance in the high resolution dataset showed per-
haps an intermediate level of difficulty in correctly classi-
fying spectra (Table 4) and a corresponding intermediate
degree of bias. The results suggest that as the spectra
become easier to classify, the degree of bias due to
repeated model fitting declines. This generalization is
speculative in that it is based solely on these three related
datasets and should be investigated in other datasets.
Also, it should be pointed out that bias may be quite low
in situations where there are only a few m/z values that can
distinguish spectra. In this case one could speculate that
repeated model fittings may identify primarily the same
chromosome and therefore lead to very little bias.
Conclusions
This paper presents a genetic algorithm based on descrip-
tions in earlier work. It was difficult to exactly reproduce
performance of the original algorithm because important
aspects were not well described and questions directed to
the associated website were unacknowledged. Conse-
quently, the GA's implementation described here is likely
different than that made to produce the published find-
ings. In particular, there are ambiguities concerning the
manner in which more "fit" chromosomes are chosen to
produce the subsequent generation, how chromosomes
of different lengths may be produced and combined, and
the possible use of penalization or other means to obtain
parsimonious models. Despite these potential differences
some aspects of the original algorithm's performance are
likely shared with those of the model developed here.
Some modification of the algorithm to guard against over-
fitting seems necessary to obtain good performance. In
particular, defining the fitness function simply as training
set classification accuracy produces models with too many
clusters. Here, a penalization based on the number of
clusters and markers was imposed that improved algorith-
mic performance. A cross-validation procedure was incor-
porated to choose the penalization parameters – this
resulted in algorithmic performance similar to other clas-
sification schemes. Results based on this type of algorithm
should be accompanied by a clear description of how
individual models are generated, e.g. what penalization
parameters or other means of reducing the number of
clusters are included and how they were chosen.
There is randomness and lack of reproducibility in model
performance that depends on order of cases, random
choice of initial chromosomes, and how the fitness func-
tion determines the subsequent chromosomes. Conse-
quently, for a fixed training dataset, the algorithm can
produce many chromosomes that perform well simply by
repeatedly running the algorithm. There may be a tempta-
tion to use the algorithm repeatedly and evaluate test set
performance to select the final model(s). While this can
be a problem for classification algorithms in general, the
random characteristics of this procedure may make it
especially hard to resist. Here we saw some sense of the
bias resulting from, such an approach. As the discussion
regarding bias demonstrates, the reported sensitivities and
specificities cannot be adequately assessed without very
detailed description of the models' discovery. In this
sense, those who employ such a scheme must supply
complete information regarding the entire process used to
choose the given models and users of algorithms that have
this property of producing multiple models from a fixed
dataset must be aware of this potential bias.
Overall, once modifications have been incorporated to
address the overfitting concerns, the algorithm's perform-
ance seems comparable to other methods. It should be
noted that the final models produced by this GA are of a
simple to interpret form that may be based on a small
number of markers and clusters. This simplicity is not nec-
essarily present for other algorithms (e.g. boosting, neural
nets, support vector machines). This algorithm seems a
reasonable option for creating discrimination models
though it does have disadvantages that might guide ana-
lysts to choose a different approach.
Methods
Data sources
The low resolution dataset, DS1, was obtained from a Pro-
teinChip Biomarker System-II (PBS-II) surface-enhanced
laser desorption ionization time-of-flight (SELDI-TOF)
instrument produced by Ciphergen Biosystems, Inc. of
Fremont, CA, USA using a WCX2 ProteinChip array, also
produced by Ciphergen. Further details regarding samplePage 11 of 13
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the NCI-FDA website. While data from earlier low resolu-
tion datasets were available from the NCI-FDA website,
these data (labeled 8-7-02) were chosen because the base-
line does not appear to have been subtracted. As discussed
by others [17] it does not appear possible to reproduce the
original results of the genetic algorithm after baseline sub-
traction has been performed.
The high resolution dataset, DS2, was obtained from a
hybrid quadrupole time-of-flight mass spectrometer
(QSTAR pulsar I, Applied Biosystems, Inc. Framingham,
MA, USA) modified to read the WCX2 ProteinChip. Addi-
tional information regarding handling and preparation of
samples is available in [12].
Normalization of the two datasets was performed differ-
ently. For the low resolution data the spectra were rescaled
linearly so the smallest value was 0 and the largest was 1.
This was described in an earlier document on the NCI-
FDA website (since removed) and was the approach
described in [17]. This transformation has no effect on the
genetic algorithm since additional rescaling is done
within each individual spectrum on a chromosome by
chromosome basis. This may have some effect (relative to
performing no normalization) on the boosting and PAM
algorithms but it is likely to be quite small as the maxi-
mum value for each spectrum was 100 (except one which
reported a max value of 99.75) and the minima lay
between 3.75 and 3.95 – so the effect was nearly one of
applying the same transformation to each spectrum. The
PAM and boosting algorithms were implemented after an
additional normalization step that equalized the average
intensity for each spectrum.
For the DS2 data, once the raw values were aggregated into
7106 bins the spectra were normalized to have the same
average intensity. Here it seemed necessary to try to
address the fact that the intensities for samples processed
later were generally less than those processed earlier – see
the QC document on the NCI-FDA website and [12].
Again, the normalization has no effect for the genetic
algorithm. For the other algorithms it seemed important
to try to address this temporal effect.
Data processing
Computing for all the classification algorithms (GA,
boosting, and PAM) was done using the R programming
language. Results for the PAM algorithm were obtained
using the pamr package available from the R website [22].
On the website housing supporting information for this
paper [16], full details are available showing the code and
steps necessary to reproduce the findings presented in this
paper.
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